|
Recombinant pseudo-adenovirus particle based on the genome of human adenovirus of serotype 5 and the method of its use are characterised. The presented particle comprises an expressing cassette with the insert of the hemagglutinin gene of influenza virus, at that the hemagglutinin gene of influenza virus was used as hemagglutinin of strain A/Brisbane/59/2007(H1N1) with the nucleotide sequence preliminary optimised for expression in human cells, presented in SEQ ID N0:2. The said haemagglutinin gene of influenza virus is cloned into an expression cassette comprising the signal of polyadenylation SV40 under control of the cytomegalovirus promoter. The presented invention can be used to induce specific immunity against influenza virus of A subtype H1 and H5 when administered to a subject in an effective amount, by providing enhanced expression of the recombinant hemagglutinin of influenza virus A/Brisbane/59/2007 (H1N1). |
|
|
Versions of hemagglutinin and neuraminidase of influenza virus Invention refers to biotechnology, virology and medicine. A virus is characterised by the fact that it contains a genomic segment coding a polypeptide with SEQ ID NO:18. There are also described immunogenic compositions containing these viruses, and a method for preventive treatment of influenza A virus infection. The invention may be used in medicine. |
|
|
Flu virus, capable of infecting canidae and its application Invention relates to the field of biotechnology and virology. Claimed are isolated strains of the flu virus, capable of infecting canidae and cause respiratory diseases in canidae. Compositions and methods for inducing immune response against the flu virus in canidae are also described. |
|
|
Invention refers to medical biotechnology, and concerns influenza virus strains What is presented is the influenza virus strain A/Hongkong/1/68/162/35 (H3N2) deposited in the State Collection of Viruses of Ivanovskiy Scientific and Research Institution of Virology of Russian Academy of Medical Sciences, No.2442, that is a donor of internal genes for producing reassortant strains and prepared by passaging an agent through chicken embryos. The presented attenuation donor is used to produce the reassortant stains: A/SPb/GK/09 (H1N1) and A/HK/Astana/6:2/2010 (H5N1) deposited in the in the State Collection of Viruses of Ivanovskiy Scientific and Research Institution of Virology of Russian Academy of Medical Sciences, Nos. 2627 and 2626, respectively that inherit high reproductivity (9,5 lg) and an attenuation phenotype (ca) and thermal sensitivity (ts) respectively from the donor. |
|
Characterised is recombinant pseudo adenoviral particle based on human being adenovirus genome of the 5-th serotype and method of its use. Provided particle contains expressing cassette with haemagglutinin gene of influenza virus being included. As a haemagglutinin gene of influenza virus, haemagglutinin gene of A/Perth/16/2009(H3N2) strain with pre-optimised for expression in human being cells nucleotide sequence presented in SEQ ID NO:2. The specified haemagglutinin gene of influenza virus of A/Perth/16/2009(H3N2) strain is cloned in expressing cassette containing polyadenylation signal SV40 under control of cytomegalovirus promoter. Presented invention may be used for induction of specific immunity to influenza virus A of H3N2 subtype during injection in efficient quantity. |
|
Characterised is recombinant pseudo adenoviral particle based on human being adenovirus genome of the 5-th serotype and method of its use as a component for production of vaccine for influenza virus A of H1N1 subtype. Presented recombinant particle contains expressing cassette including SV40 polyadenylation signal and cytomegalovirus promoter with influenza virus haemagglutinin gene being included. As influenza virus haemagglutinin gene, haemagglutinin gene of strain A/California/07/2009(H1N1) is used with pre-optimised for expression in human being cells nucleotide sequence provided in SEQ NO:2. These inventions allow raising specific immunity to influenza virus A of H1N1 subtype by provision of overexpression of haemagglutinin gene of influenza virus A/California/07/2009(H1N1). |
|
Vaccine strain for influenza virus A/17/mallard/Netherlands/00/95(H7N3) is proposed. Strain A/17/mallard/Netherlands/00/95(H7N3) is harmless for laboratory animals. Strain A/17/mallard/Netherlands/00/95(H7M3) has antigenic actuality and attenuation thus meeting the requirements to vaccine strains included in influenza live vaccine, and may be used for production of influenza live and inactivated intranasal vaccine in health care service for influenza prevention. |
|
|
Method of virus treatment by ultracentrifugation in sugar concentration gradient (versions) Treatment methods of inactivated virus or fragmented virus (versions) are proposed. Methods involve addition of virus preparation to sugar gradient and further centrifugation to obtain peak fraction. Then, peak fraction is extracted to obtain cleaned virus. With that, sugar gradient is obtained by continuous ultracentrifugation of the first and the second buffer sugar solution. Besides, the first buffer sugar solution includes the first physiological buffer, and the second buffer sugar solution includes the second physiological buffer that is the same or different from the first physiological buffer. As per one version, sugar concentration in the first buffer solution is equivalent to saccharose concentration of 35 to 50 wt %, and sugar concentration in the second buffer solution is equivalent to saccharose concentration of 50 to 65 wt %. Besides, the second buffer sugar solution has higher density in comparison to that of the first one. As per the other method version, density of the first buffer sugar solution is 1.15 kg/l to 1.23 kg/l, and density of the second one is 1.23 kg/l to 1.32 kg/l. |
|
Invention relates to the field of microbiology and relates to the strain of flu virus of H16N3-subtype. The strain of bird flu virus A/common gull/Altai/804/2011/H16N3-subtype is described, deposited in the State Collection of Viral Infectons and Rickettsial diseases of the Federal Budget Institution of Science State Science Centre of Virusology and Biotechnology "Vector" under the registration number V-583. The strain was isolated from a common gull (Larus canus). The strain may be used to produce a polyclonal serum to determine affinity of the flu virus to H16-subtype, and also may be used as a control reference sample when assessing specificity of test systems on the basis of PCR. |
|
|
Method for producing preparation containing viral antigens and using preparation Invention refers to molecular biology, genetic engineering and virology. What is presented is a method for producing a preparation containing the viral antigens, involving a) cell inoculation with an infectious in the fluid, b) reproduction of the above virus in the above cells, c) collection of the above reproduced virus, d) inactivation of the above collected virus, and e) treatment of the above inactivated virus with a detergent to produce the preparation containing the viral antigens. |
|
Method for influenza virus purification Invention refers to biotechnology and describes a method for preparing a purified concentrate of influenza virus; the method involves microfiltration of a virus-containing allantoic fluid in filter elements of the size of 0.1-0.2 mcm and further diafiltration in a phosphate buffer solution containing sodium chloride 0.25-0.5 M, EDTA or sodium citrate, concentration of influenza virus on membranes with a cuttoff threshold of 300-500 kDa and further diafiltration in a phosphate buffer solution containing sodium chloride 0.25-0.5 M, EDTA or sodium citrate, an anionic detergent 0.02-0.002%, and ultra-centrifugation in a density gradient of saccharose prepared in a phosphate buffer solution containing sodium chloride 0.25-0.5 M, EDTA or sodium citrate, and an anionic detergent 0.02-0.002%. |
|
Strain of a flu virus A/IIV-Anadyr/177-ma/2009 (H1N1) pdm09 is proposed, which is adapted to tissues of light laboratory rodents. The strain is produced by means of multiple passage of a parent strain A/IIV-Anadyr/177/2009 (H1N1) on models of developing hen embryos, infected into the allantoic cavity, and pedigreeless laboratory white mice infected intranasally. The strain may be actively reproduced in tissues of light laboratory rodents, casing lethal pneumonia in them. The strain is deposited into the state collection of viruses of the Scientific and Research Institute of Virology named after D. I. Ivanovskiy under the No.2721. |
|
Recombinant trivalent influenza vaccine Invention refers to molecular biology and genetic engineering. What is presented is a recombinant trivalent influenza vaccine containing three types of non-replicating nanoparticles of serotype 5 human adenovirus genome each carrying the different genes of influenza virus hemagglutinin with the vaccine further containing an immunostimulant and a buffer. |
|
Lyophilised formulation containing influenza vaccine, and method for preparing it Group of inventions refers to medicine, namely to a lyophilised formulation containing an influenza vaccine, an aqueous solution prepared by lyophilisation and containing (i) he influenza vaccine, (ii) a hydrophobic amino acid, and (iii) arginine and an acid addition salt thereof; it also concerns a method for preparing the lyophilised formulation containing the influenza vaccine to be desalted. |
|
Method to produce a flu virus is proposed, according to which hens are injected with a vaccine against flu, eggs are collected from vaccinated hens, the process of embryogenesis is initiated, eggs with a developing embryo are infected, introducing a flu virus into an allantoic cavity, infected eggs with developing embryos are incubated under temperature and moisture, which provide for virus replication, and the allantoic liquid is collected, which contains a virus. Also application of the flu virus and eggs produced by this method is proposed. |
|
Method to apply modified flu virus Methods are described to prevent a virus flu infection and detection of efficiency of a flu virus vaccine using a molecule of hemagglutinin (HA) of a flu virus A of subtype H5, immunogenicity of which is increased by replacement of amino acids in the HA sequence. |
|
Protein of flu virus hemagglutinin is disclosed, as well as a molecule of nucleic acid, which codes such protein, a vaccine for treatment or prevention of infections, which are mediated by a flu virus, a set and also methods to produce protein and vaccines. The protein of hemagglutinin H5 of the flu virus is characterised by the fact that in the position 223 of the series it is substituted with asparagine, and the second lysine is built into the position 328. |
|
Invention refers to veterinary virology and microbiology. What is presented is the influenza virus strain A/teal/Chany/7119/08/ subtype H15N4 deposited in Collection of Microorganisms of Federal State-Funded Institution of Science State Research Centre for Virology and Biotechnology "Vector", registration No. V-563. The invention may be used for preparing an antigen-containing substrate and serum for serum diagnosis of subtype H15N4 influenza, as well as a component of a polyclonal serum set for various subtypes of influenza A virus (H1-H16) for the purpose of typing newly nature-derived versions of influenza virus in hemagglutination-inhibition reaction (HIR), as well as for the purpose of detection of subtype H15 influenza virus antibodies in wildlife blood serum for assessment of indirect immunity for influenza virus of the given subtype in HIR. |
|
Influenza virus strain for producing live influenza intranasal vaccine for adults and children A/Pert/16/2009(H3N2) strain is produced with the use of genetic reassortation by epidemic virus A/Pert/16/2009(H3N2) mating with the cold-adapter heat-sensitive A/Leningrad/134/17/57(H2N2) strain that is an attenuation donor safe for adults and children. The prepared strain is deposited in the State Collection of Viruses of Ivanovsky Research Institution of Virology of the Russian Academy of Medical Science, No. 2630. |
|
|
What is presented is the reassortant A/17/New Caledonia/99/76(H1N1) vaccine strain of influenza A virus. Said strains replicates actively in growing chicken embryos at optimum temperature 33°C; it is characterised by thermal sensitivity, cold adaptation and attenuation for laboratory animals. The reassortant has inherited the genes coding surface glycoproteins - hemagglutinin and neuraminidase from an epidemic type A(H1N1) virus, and and six genes coding non-glycosylated proteins from the attenuation donor A/Moscow/21/17/65(H2N2). Thereby the A/17/New Caledonia/99/76(H1N1) vaccine strain has such genome formula and biological properties to meet the requirements for the vaccine strains for live influenza vaccines according to the Manufacturer's Monograph 42-0417. |
|
Influenza virus strain for producing live and inactivated influenza vaccine A/17/quail/Hong Kong/97/84(H9N2) strain is prepared by genetic reassortation by crossing of apatogenic avian virus A/quail/Hong Kong/6/97(H9N2) and the cold-adapted thermally sensitive A/Leningrad/134/17/57(H2N2) strain - an attenuation donor. The prepared strain is deposited in the Collection of Viruses of Ivanovsky Research Institution of Virology of the Russian Academy of Medical Sciences, No. 2631. |
|
|
Strain A(H3N2) - A/8/Perth/16/09 is a reassortant prepared on the basis of two viruses: epidemic A/Perth/16/2009 (H3N2) and high-reproducibility donor A/Puerto Rico/8/34 (H1N1). The strain has inherited the genes HA and NA coding the surface virus proteins from the epidemic virus, and the genes PB1, PB2, PA, NP, M, NS coding the internal non-glycolised proteins from the donor. The strain A(H3N2) - A/8/Perth/16/09 is applicable for production of a monovalent and three-component vaccine for immunisation against influenza virus subtype A(H3N2). |
|
Reassortant rem8-vaccine strain of suptype h1n1 influenza a virus What is offered is a vaccine strain of A ReM8 (H1N1) virus deposited in the State Collection of Viruses No. 2632. High effectiveness of the prepared reassortant ReM8, as well as its immunogenicity shown by immune protection experiments in mice makes it possible to consider the reassortant virus ReM8 as a candidate strain for production of inactivated and subunit vaccines for pandemic influenza A (H1N1) virus in 2009. |
|
What is produced is a new strain A/Salekhard/01/2009(H1N1)v of subtype H1N1 influenza virus deposited in in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-538. |
|
Subtype H1N1 influenza virus strain A/Russia/Ol/2009-ma is intended for study of the efficacy of therapeutic and preventive preparations for influenza virus in experiments in vitro and in vivo. The strain is deposited in the Collection of Cultures of the State Research Centre for Virology and Biotechnology "Vector" No.V-511. The strain is applied in determining definition influenza activity of the preparations in vitro with using MDCK cells. The strain provides a basis to create an adequate model for studying of activity of antiviral preparations for subtype H1N1 influenza virus in vivo consisting in intranasal infection of Balb/c mice of weight 14-16 g with the given strain. |
|
Recombinant swine influenza virus h1n1 vaccine and method for preparing it Engineered recombinant protein molecule for preparing a recombinant vaccine for an infection caused by swine influenza virus (HlNlv-2009). The molecule consists of a residue of methionine, a sequence of extracellular M2 protein domain of 2 to 24 amino acids and a sequence of a nuclear hepatitis B virus antigen of 4 to 149 amino acids. The molecule is able to form virus-like particles. There are also disclosed a recombinant nucleic acid coding such molecule, a vector for its expression, virus-like particles formed by such molecules and a vaccine based on the prepared virus-like particles. |
|
Invention relates to biotechnology and virology. Compositions and methods used to induce immune response against the influenza virus in canines using novel strains, polynucleotides or polypeptides thereof are described. The invention can be used in veterinary. |
|
Influenza vaccine and method for preparing it Invention refers to medicine and concerns an influenza vaccine and method for preparing it. Substance of the invention involves the influenza vaccine containing the coupling of purified influenza virus antigens and a polymeric carrier representing 2-methyl-5-vinylpyridine and N-vinylpyrrolidone copolymer in proportions 1: 5-30, and a method for preparing the influenza vaccine involving the cultivation of influenza virus strain in chicken embryos to produce a purified viral concentrate that is followed by inactivating, splitting the viral concentrate to produce the purified influenza virus antigens and coupling with the polymer carrier representing 2-methyl-5-vinylpyridine and N-vinylpyrrolidone copolymer in proportions 1: 5-30. |
|
FIELD: medicine. SUBSTANCE: group of inventions is referred to the area of medicine, namely to the area of virusology, and is related to virosomes containing hemagglutinin extracted from influenza virus produced in the cell lines, compositions, containing said virosomes, means of manufacturing and applications. The essence of the invention including virosomes containing hemagglutinin extracted from influenza virus produced in the bird cell lines, compositions, containing said virosomes, application of virosome as a vessel, set, methods of vaccination, methods of treatment and methods of virosome production. EFFECT: production of virosomes having improved merging capability and increased immunogenicity. 21 cl, 3 tbl, 5 dwg |
|
Strain of bird flu of A/Herring gull/Mongolia/454/08/ H13N8-subtype was deposited in Collection of microorganisms of Federal State Institution of Science "State research centre of virology and biotechnology "Vector" Rospotrebnadzor under registration number V-436 and is used in obtaining antigen-containing substrate and serum for diagnostic purposes. Claimed strain can be used for serodiagnostics of influenza of H13-subtype in RHAI, as component of panel of polyclonal serums to different subtypes of influenza A virus (H1-16) for typing versions of influenza virus newly isolated from nature in reaction of hemagglutination inhibition (RHAI), as well as for identification of antibodies to virus of H13-subtype influenza in serums of wild animal blood for estimation of population immunity to virus of said subtype influenza in RHAI. |
|
|
Nucleic acid contains a gene segment of a influenza virus and a bacteriophage polymerase promoter or a complementary chain of said nucleic acid. What is described is a composition containing a cell or a material produced of a cell according to this invention, or a virus, or a material produced of a viral particle according to this invention. The invention can be used in medicine. |
|
Cancer treatment with application of viruses fluoropyrimidines and camptothecins Claimed group of inventions relates to medicine, namely to oncology, and can be applied for treatment of neoplasm, as well as for producing medication for it treatment. For this purpose virus of Newcastle disease in combination with gluoropyrimidine and camptothecin compound during one or more cycles in total quantity, effective for subject treatment. |
|
Strain is produced by cross breeding of sterile equine influenza virus A/horse/Prague/1/1956(H7N1) and cold-adapted vaccine strain A/17/California/09/38(N1) on the basis of an attenuation donor A/Leningrad/134/17/57(H2N2) and contains neuraminidase of pandemic influenza virus A//California/07/09(H1N1) and hemagglutinin of equine influenza virus A/horse/Prague/1/1956(H7N7). The strain RN1/09-swine A(H7N1) is deposited in the State collection of viruses of Institution of Russian Academy of Medical sciences of D.I. Ivanovsky Institute of virology of Russian Academy of Medical Science, No. GKV 2473 and can be applied for influenza virus neuraminidase N1 antibody assay. |
|
Method of preparing biologically active complex Invention refers to molecular biology, immunology, virology and concerns a method of preparing a biologically active complex. A method is enabled by mixing an aqueous suspension of a modified rod-like virus particle with an aqueous solution of polypeptide. The modified virus particle is presented by a reaction product of 1 weight fraction of rod-like virus particle and 0.01-0.1 weight fractions of water-soluble polymer and cationic groups in an aqueous medium. 1 weight fraction of the modified rod-like virus particle is mixed with 0.1-25 weight fractions of polypeptide. |
|
|
Biologically active complex exhibiting influenza virus protective activity Invention refers to molecular biology, immunology, virology. What is described is a biologically active complex which can be used for preparing vaccine and therapeutic preparations for viral and other infectious diseases and other purposes. |
|
|
Method of preparing influenza vaccine Invention refers to medicine, and concerns a method of preparing a influenza vaccine. Substance of the invention includes influenza virus infection of chicken embryos, incubation, sampling of a virus-containing fluid, purification of influenza virus, concentration and final virus purification by gel filtration HW-65C carrier column chromatography. Purified virions are destroyed by the detergent β-octylglucoside to be removed then. Three half-finished vaccines prepared with the use of received with use of H1N1, H3N2 and B serotypes are combined so that the hemagglutinin concentration in each serotype is about 30 mcg/ml. |
|
|
Invention can be used in biotechnology, and can be used in practical health services for preventing seasonal influenza incidence in adults and children by a live influenza intranasal vaccine of the A/Solomon Islands/03/2006 (H1N1) influenza virus. Vaccine strain of B/60/Florida/04/181 (H1N1) is a reassortant prepared by cross breeding an epidemic B/Florida/07/04 virus and a cold-adapted thermally sensitive B/USSR/60/69 virus being a human-safe attenuation donor. The vaccine strain B/60/Florida/04/181 (H1N1) strain replicates actively in growing chicken embryos at optimum temperature 32°C, is characterised by thermal sensitivity and cold adaptation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor. |
|
Vaccine strain of A/17/Solomon Islands/06/9 (H1N1) is a reassortant prepared by cross breeding an epidemic A/Solomon Islands/03/2006 (H1N1) virus and a cold-adapted thermally sensitive A/Leningrad/134/17/57 (H2N2) virus being a human-safe attenuation donor. The vaccine strain A/17/Solomon Islands/06/9 (H1N1) strain replicates actively in growing chicken embryos at optimum temperature 32°C, is characterised by thermal sensitivity and cold adaptation, The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor. The A/17/Solomon Islands/06/9 strain is areactogenic for adults and children in intranasal introduction. |
|
Vaccine strain of B/60/Brisbane/08/83 (H1N1) influenza virus is a reassortant prepared by cross breeding an epidemic B/Brisbane/60/2008 virus and a cold-adapted thermally sensitive B/USSR/60/69 (H2N2) virus being a human-safe attenuation donor. The B/60/Brisbane/08/83 strain replicates actively in growing chicken embryos at optimum temperature 32°C. The strain is characterised by thermal sensitivity and cold adaptation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor. The B/60/Brisbane/08/83 strain is areactogenic for adults and children in intranasal introduction. In reactogenecity, the vaccine strain of B/60/Brisbane/08/83 influenza virus meets the requirements specified in the Manufacturer's Monograph 42-0504-4097-04 to vaccine strains for live dry allantoic influenza vaccine for intranasal application. |
|
Conditionally defective particle of influenza virus and methods of producing thereof (versions) Disclosed is a conditionally defective particle of influenza virus with the absence of a nucleic acid segment of influenza virus selected from a group of segments, mainly coding acid polymerase (PA), basic polymerase 1 (PB1) and basic polymerase 2 (PB2). The conditionally defective particle of influenza virus is used for induction of influenza virus defence. Also, a method of producing such particles, a pharmaceutical composition containing such particles, its application and a method of induction of influenza virus defence are described. |
|
Method of obtaining life culture vaccine against influenza virus Invention relates to field of medicine and deals with method of obtaining lice culture influenza vaccine. Essence of the invention includes method of obtaining virus-containing substance by cultivation of one of cold-adapted influenza virus reassortants with enoculation dose, with multiplicity of infection not lower than 0.0001 EID50/cell in MDCK cell culture on micro-carriers, which have concentration not less than 1 g/l, with application as micro-carrier material of porous polypropelene, in supporting serum-free nutritional medium, containing proteolytic enzyme in amount 0.25-50.0 mcg/ml, and stabilising additive, which includes sorbitol, or sucrose, or peptone from soya in concentration 0.5-4.0 wt%, collection of virus-containing liquid after cultivation is carried out at least 2 times when specific influenza virus activity before each collection of virus-containing liquid reaches at least 7.0 Ig EID50/ml, concentration and purification of virus substance from ballast admixtures, introduction into purified substance before drying of stabilising additives, with application as such of either proline, glycene, lactose, glutamine-acidic sodium, sucrose, gelatins in final concentration (1.5-5), (1.5-5), (1.5-10), (1.5-5), (5-30) and (1-10) wt % respectively, or sucrose, gelatose and soya peptone in final concentration (1-8), (1-8) and (1-8) wt % respectively, or sorbitol and gelatose in final concentration (3-8) and (3-8) wt % respectively. |
|
|
Vaccine strain of A/17/Brisbane/07/28 (H1N1) influenza virus is a reassortant prepared by cross breeding an epidemic A/ Brisbane /59/07 (H1N1) virus and a cold-adapted thermally sensitive A/Leningrad/134/17/57 (H2N2) virus being a human-safe attenuation donor. The A/17/Brisbane/07/28 (H1N1) strain replicates actively in growing chicken embryos at optimum temperature 32°C. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor. The A/17/Brisbane/07/28 (H1N1) strain is areactogenic for adults and children in intranasal introduction. In reactogenecity, the vaccine strain of A/17/Brisbane/07/28 (H1N1) influenza virus meets the requirements specified in the Manufacturer's Monograph 42-0417-4097-03 to vaccine strains for live dry allantoic influenza vaccine for intranasal application. |
|
A/17/Brisbane/07/1 (H3N2) strain replicates actively in growing chicken embryos at optimum temperature 32°C. A reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus. The other six genes coding internal non-glycosylated proteins have been inherited from an attenuation donor. The A/17/Brisbane/07/1 (H3N2) strain is areactogenic for adults and children in intranasal introduction. The invention can be used in practical health services for preventing seasonal influenza incidence in adults and children by a live influenza intranasal vaccine of the A/17/Brisbane/07/1 (H3N2) strain. |
|
B/60/Malaysia/04/898 strain actively replicates in growing chicken embryos at optimum temperature 32-33°C. It is characterised by thermal sensitivity and cold adaptation. A reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus. The other six genes code internal non-glycosylated proteins from an attenuation donor. The B/60/Malaysia/04/898 strain is areactogenic for adults and children in intranasal introduction. |
|
Vaccine strain A/17/California/2009/38 (H1N1) - reassortant, obtained by crossing new pandemic virus A/17/California/2009 (H1N1) with cold-adapted temperature-sensitive virus A/Leningrad/134/17/57 (H2N2) -donor of attenuation, harmless for people. Strain A/17/California/2009/38 (H1N1) actively multiplies in developing chicken embryos at optimal temperature 32-33°C, is characterised by temperature sensitivity and cold adaptation. Reassortant inherited genes, coding superficial antigens of virus hemagglutinine (HG) and neuraminidase (NA), from potentially pandemic virus and the remaining six genes, coding internal unglycolised proteins from donor of attenuation. |
|
Canine influenza virus, compositions containing said virus and application thereof Present invention relates to biotechnology and specifically to isolated canine influenza virus subtype H3N8 which contains HA protein. Described also is a composition which contains an attenuated or inactivated virus and isolated or purified proteins HA, NM, NP, M1, NS1, PA, PB1 and pB2 and fragments thereof. |
|
Method of influenza vaccination of birds Invention refers to veterinary science. The method implies that the introduced vaccine is mixed with Myramistin. Myramistin is introduced intranasally by 0.2-0.3 ml into each nasal passage of a bird. |
|
|
Vaccines and methods of treating canine influenza Present invention refers to production of new vaccines and methods of treating the diseases associated with canine influenza virus. The method of immunisation of a dog against influenza virus involves introduction to a specified dog of a therapeutically effective amount of the vaccine containing at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog, and the amount of the specified virus is 10 to 10000 GA units, and the vaccine additionally contains an adjuvant where the adjuvant can be chosen from the metabolised adjuvant, b) the non-metabolised adjuvant, c) 2% alum, d) 5% alum, e) Quil A, and f) cholesterol or any combination thereof. The method for preparing the vaccine against canine influenza virus includes making the composition containing the therapeutically effective amount of at least one attenuated or inactivated H3N8 influenza virus where the specified virus is recovered from a dog. Application of the vaccine prepared by the method for immunisation of dogs against influenza virus. |
|
Method for prevention of bird's flu type a Simultaneously the following operations are carried out: one-time vaccination of bird with inactivated emulsified vaccine against bird's flu from subtype H5N2 and feeding of chemical preparation "Abaktan-R" in dose of 20 mg/kg of body weight once a day during 14 days. |
|
|
Immunogenic vaccine composition comprises macromolecular protein structure containing proteins of bird influenza virus HA, NA, and Ml and a carrier or dilution agent. The suggested group of inventions provides safety recombinant vaccine practice and highly immunogenic self-organised macromolecules integrated in plasmamembranes comprising multivariate replicas of structural protein of bird influenza virus demonstrating neutralising epitopes in native conformations. |
Another patent 2513109.